Dr. Rangasamy Ramanathan of Los Angeles General Medical Center presents published data showing EHMD implementation is a life saver.
$1.8 million
2 years or more by reducing length of hospital stay and use of parenteral nutrition
Duarte, California
,
May 3, 2024
/PRNewswire/ — Prolacta Biosciences, the world’s leading hospital provider of 100% human milk-based nutritional products for critically premature infants, today announced that Drs.
Rangasami Ramanathan
Chair of the Department of Pediatrics and Professor of Neonatal Medicine at Los Angeles General Medical Center and PIH Good Samaritan Hospital presents a publication on the economic and clinical benefits of implementing a human milk-only diet (EHMD) for very low birth weight (VLBW) infants. Publish the data. ) Infants during the 2024 Pediatric Society (PAS) Meeting
Saturday, May 4th
,
6:30pm to 8:00pm ET
in
Toronto
.
PAS connects thousands of leading pediatric researchers, clinicians, and medical educators around the world to advance scientific discovery and foster innovation in child and adolescent health.
Dr. Ramanathan’s presentation will summarize data published in peer-reviewed journals.
Breastfeeding medicine.
This symposium, entitled “Exclusive Breastmilk-Based Feeding: A Cost-Effective Way to Reduce Morbidity in Preterm Infants,” will discuss the actual cost savings from Level III neonatal intensive care units (NICUs). Focusing on effectiveness analysis data, it shows:
-
Adopting Prolacta’s EHMD in VLBW infants
$1.8 million
cost reduction (or
31.8 thousand dollars
per infant over 2 years by reducing the average length of stay in the hospital by 6.3 days per infant and the average number of days on parenteral nutrition (PN) by 6.8 days per infant.
1
-
When combined with cost avoidance from improved clinical outcomes, the estimated two-year financial impact, excluding insurance reimbursement, is:
$913,840
(
$16,032
per infant).
1
“Our study shows that implementing EHMDs can be a cost-effective approach in improving health outcomes for preterm infants,” said Dr. Ramanathan. “The length of stay and days of parenteral nutrition were significantly reduced, directly leading to significant NICU cost savings.”
“This real-world experience in a safety-net hospital provides further evidence that EHMDs are not only optimal for premature infants, but can also be an economically wise decision for neonatal care providers.”
Melinda Elliott
, MD, FAAP, practicing neonatologist and Chief Medical Officer of Prolacta, Inc. “PAS participants are encouraged to attend the symposium to learn more about the clinical and economic benefits of EHMD implementation.”
To attend the symposium, which includes a panel discussion, register here.
Jonathan Swanson
M.D., and
Jenelle Ferry
MD, Moderator
erin hamilton spence
MD, Director of Clinical Education and Professional Development at Prolacta.
Real-world evidence demonstrating improved outcomes and reduced costs
Extensive real-world data supports that the implementation of EHMDs can significantly improve the health outcomes of premature infants and provide significant cost savings for hospitals. Analysis of data from 2019 to 2022 from more than 3,000 patients at more than 60 U.S. hospitals shows that implementing EHMDs improves health outcomes, lowers costs, and provides a 2.6x return on investment for every dollar spent. It turned out that the rate was obtained.
2
Similarly, a 2023 peer-reviewed report found that implementing EHMDs resulted in a 3x return on investment per dollar due to fewer comorbidities and shorter hospital stays in very low birth weight infants. found.
3
There is a lot of real-world evidence supporting human milk-based fortifiers (HMBF). It has been clinically proven in over 20 peer-reviewed clinical studies that using HMBF as part of his EHMD compared to milk-based fortifiers (BMBF): .
-
Decreasing mortality and morbidity
4-6
-
Reduced incidence of feeding intolerance
7
-
achieved sufficient growth
8-10
-
Reduced incidence of bronchopulmonary dysplasia (BPD)
4, 7, 8, 11
-
Reduced incidence of retinopathy of prematurity (ROP)
4,11,12
-
Reduced incidence and evaluation of late-onset sepsis
4,11,12
-
Reducing the risk of necrotizing enterocolitis (NEC)
4, 7, 13
-
Improved long-term outcomes such as neurodevelopment
14,15
-
Shortened NICU stay
7
-
Reducing hospitalization costs
1, 3, 7, 16, 17
-
Growth is improved in term infants recovering from surgery for single ventricle physiology (SVP)
18
About Prolacta Bioscience
Prolacta Bioscience® is a global life sciences company dedicated to advancing the science of Human Milk® to improve the health of critically ill infants and premature infants. Over 100,000 extremely premature babies
19
People around the world have benefited from Prolacta’s breast milk-based products, which have been evaluated in more than 20 peer-reviewed clinical studies. Hospitals that adopt Prolacta’s unique breast milk diet experience up to a 3x return on investment.
3
Operating the world’s first pharmaceutical-grade human milk processing facility, Prolacta conducts more than 20 validated tests for screening and testing human milk and maintains the most stringent quality and safety standards in the industry. Prolacta’s manufacturing process uses vat pasteurization to ensure pathogen inactivation while preserving nutritional content and biological activity.Learn more about
www.prolacta.com
X
,
,
and
.
Media contact:
Lauren Cosmont
Lkosmont@prolacta.com
310-721-9444
References
-
Tetarbe M, Chang MR, Barton L, Cayabyab R, Ramanathan R. Economic and clinical impact of the use of breast milk-derived fortifiers in very low birth weight infants.
breastfeeding medicine
. 2024 Feb;19(2):114-119. doi: 10.1089/bfm.2023.0163 Epub 2024 January 30. PMID: 38294868. -
Data on file. Hospital-provided outcomes analysis from 2019 to 2022.
-
Swanson JR, Becker A, Fox J, et al. Introducing an exclusive breast milk diet for preterm infants: Practical experience in a diverse NICU.
BMC
Pediatrics
. 2023;23(1). doi.org/10.1186/s12887-023-04047-5 -
Hare AB, Peluso AM, Hawthorne KM, et al.Beyond prevention of necrotizing enterocolitis: Improving outcomes with a breast milk-based diet [published correction appears in
Breastfeed Med
. 2017 Dec;12 (10):663].
breastfeeding medicine
. 2016;11(2):70-74. doi:10.1089/bfm.2015.0134 -
Abrams SA, Shanler RJ, Lee ML, Rechtman DJ. Mortality and morbidity were higher in very preterm infants fed diets containing cow’s milk protein products.
breastfeeding medicine
. 2014;9(6):281-285. doi:10.1089/bfm.2014.0024 -
Cristofaro EA, Schanler RJ, Blanco CL, et al. A randomized trial of exclusive breast milk versus preterm formula feeding in extremely premature infants.
J
Pediatrics
. 2013;163(6):1592-1595.e1. doi:10.1016/j.jpeds.2013.07.011 -
Assad M, Elliott MJ, Abraham JH. Reduced costs and improved feeding tolerance in VLBW infants fed exclusively with breast milk.
J
perinator
. 2016;36(3):216-220. doi:10.1038/jp.2015.168 -
Huston R, Lee M, Ryder E, et al. Early fortification of enteral feeding for infants <1,250 g birth weight receiving a breast milk diet containing a human milk-based fortifier.
J Neonatal Perinatal Medicine
. 2020;13(2):215-221. doi:10.3233/NPM-190300 -
Houston RK, Markel AM, McCurry EA, Gardiner SK, Sweeney SL. Improves growth in infants under 1250 grams on a breast milk-only diet.
Nettle
Clin
practice
. 2018;33(5):671-678. doi:10.1002/ncp.10054 -
Hare AB, Hawthorne KM, Cetta KE, Abrams SA. Breastfeeding supports proper growth in infants weighing 1250 grams or less at birth.
BMC resolution notes
. 2013;6:459. Published on November 13, 2013. doi:10.1186/1756-0500-6-459 -
Delaney Mante E, Parks PH, Swanson JR. A team-based diet dedicated to breastfeeding.
advanced neonatal care
. 2019;19(6):460-467. doi:10.1097/ANC.0000000000000676 -
O’Connor DL, Kiss A, Tomlinson C Fortification of breast milk with human milk and milk-based fortifiers in infants born weighing less than 1250 g: a randomized clinical trial. [published correction appears in
Am J Clin
Nutr
. 2019
Aug 1
;110(2):529] [published correction appears in
Am J Clin
Nutr
. 2020
May 1
;111(5):1112].
Am J. Klin
Nettle
. 2018;108(1):108-116. doi:10.1093/ajcn/nqy067 -
Sullivan S, Shanler RJ, Kim JH, et al. Diets based solely on breast milk have been associated with lower rates of necrotizing enterocolitis than diets containing breast milk or milk-based products.
J
Pediatrics
. 2010;156(4):562-7.e1. doi:10.1016/j.jpeds.2009.10.040 -
Bergner EM, Shypailo R, Visuthranukul C, et al. A pilot study examining growth, body composition, and neurodevelopmental outcomes at 2 years of age in preterm infants fed exclusively with breast milk in the neonatal intensive care unit.
breastfeeding medicine
. 2020. 15(5):304-311. doi:10.1089/bfm.2019.0210 -
Rahman A, Kase J, Murray Y et al. Neurodevelopmental outcomes of very low birth weight infants fed exclusively with human milk are not influenced by growth rate.
breastfeeding medicine
. 2020;15(6):362-369. doi:10.1089/bfm.2019.0214 -
Ganapathy V, Hay JW, Kim JH. The cost of necrotizing enterocolitis and the cost-effectiveness of exclusively human milk-based products when feeding extremely premature infants.
breastfeeding medicine
. 2012;7(1):29-37. doi:10.1089/bfm.2011.0002 -
Data on file. Hospital-provided outcomes analysis from 2019 to 2022.
-
Blanco CL, Hare A, Justice LB, Rodi D, Bonaglio K, Williams PK, Machado D, Marino BS, Chia A, Takao C, Gordon EE, Ashrafi A, Cacho N, Plutz JD, Costello JM, Cooper DS, Cardiac. Neonatal Nutrition Research Group. A randomized trial of a breast milk-only diet in neonates with univentricular physiology.
J
Pediatrics
. 2022;256: 105–112. doi.org/10.1016/j.jpeds.2022.11.043 -
Data on file.Estimated number of infants given Prolacta products
January 2007
to
August 2023
.
View original content to download multimedia: https://www.prnewswire.com/news-releases/pediatric-academic-society-meeting-includes-symposium-on-cost-effectness-of- implementing-exclusive-human-milk-based -nutrition for premature infants-302135387.html
Source Prolacta Bioscience
